Case ReportRESPONSE TO INTRAVITREAL AFLIBERCEPT IN A PATIENT WITH PERIPHERAL EXUDATIVE HEMORRHAGIC CHORIORETINOPATHYSax, James MBBS*; Karpa, Michael FRANZCO, MBBS*; Reddie, Ian FRANZCO, MBBS†Author Information *The Townsville Hospital, Douglas, Queensland, Australia; and †Townsville Eye Care, Mundingburra, Queensland, Australia. Reprint requests: James Sax, MBBS, Ophthalmology Outpatients, The Townsville Hospital, 100 Angus Smith Drive, Douglas, Queensland 4814, Australia; e-mail: [email protected] None of the authors has any financial/conflicting interests to disclose. Retinal Cases & Brief Reports: May 2021 - Volume 15 - Issue 3 - p 286-288 doi: 10.1097/ICB.0000000000000787 Buy Metrics AbstractIn Brief Purpose: To draw attention to a novel treatment agent for vision loss associated with peripheral exudative hemorrhagic chorioretinopathy. Methods: The case of an 83-year-old man suffering with loss of left visual acuity vision in the context of vitreous hemorrhage secondary to peripheral exudative hemorrhagic chorioretinopathy is described. Results: Resolution of vitreous hemorrhage and subretinal hemorrhage was demonstrated after treatment with aflibercept. Conclusion: Peripheral exudative hemorrhagic chorioretinopathy is discussed in terms of its presentation, pathophysiology, and existing treatment methodologies. The report of a case of peripheral exudative hemorrhagic chorioretinopathy complicated by vitreous hemorrhage and treated with aflibercept.